Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein mono-ADP-ribosyltransferase PARP10 (PARP10), also known as ARTD10, is a member of the diphtheria toxin-like ADP-ribosyltransferase family that specifically catalyzes the transfer of a single ADP-ribose unit from NAD+ to substrate proteins, a process known as mono-ADP-ribosylation (MARylation) [1, 2, 6]. Unlike the well-known PARP1 and PARP2 enzymes which form long poly-ADP-ribose chains, PARP10 modifies target residues such as glutamate, aspartate, and lysine to regulate protein function and protein-protein interactions [2, 11, 23]. It is a multifunctional protein localized in both the nucleus and cytoplasm, where it interacts with key partners like the proto-oncoprotein c-Myc and the replication factor proliferating cell nuclear antigen (PCNA) [4, 15, 17]. PARP10 is essential for maintaining genomic integrity by facilitating translesion DNA synthesis and the restart of stalled replication forks, thereby helping cells tolerate DNA damage and replication stress [15, 19]. In the context of disease, PARP10 is frequently overexpressed in various human cancers and is considered an oncogene that promotes cellular transformation and tumor growth [15, 21, 23]. Its ability to alleviate replication stress makes it an attractive therapeutic target, as its inhibition can sensitize cancer cells to chemotherapy and radiation [3, 5, 10]. Beyond oncology, PARP10 is involved in regulating the NF-kappaB signaling pathway, mitochondrial metabolism, and innate immune responses, suggesting potential roles in inflammatory and metabolic diseases [6, 9, 15, 23]. While clinical PARP inhibitors primarily target PARP1/2, selective PARP10 inhibitors like OUL35 have been developed as chemical tools and potential drug candidates to exploit the specific vulnerabilities of PARP10-dependent tumors [6, 22]. However, the high conservation of the NAD+ binding pocket across the PARP family presents a significant challenge for achieving the necessary selectivity to avoid off-target toxicities [6, 10, 12].
Inhibition of mono-ADP-ribosyltransferase activity, which prevents the mono-ADP-ribosylation of target proteins involved in DNA repair and cell cycle progression [3, 6, 21].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein mono-ADP-ribosyltransferase PARP10 (PARP10).